Inwardly rectifying I K1 potassium currents of the heart control the resting membrane potential of ventricular cardiomyocytes during diastole and contribute to their repolarization after each action potential. Mutations in the gene encoding K ir 2.1 channels, which primarily conduct ventricular I K1 , are associated with inheritable forms of arrhythmias and sudden cardiac death. Therefore, potential iatrogenic inhibition of K ir 2.1-mediated I K1 currents is a cardiosafety concern during new drug discovery and development. K ir 2.1 channels are part of the panel of cardiac ion channels currently considered for refined early compound risk assessment within the Comprehensive in vitro Proarrhythmia Assay initiative. In this study, we have validated a cell-based assay allowing functional quantification of K ir 2.1 inhibitors using whole-cell recordings of Chinese hamster ovary cells stably expressing human K ir 2.1 channels. We reproduced key electrophysiological and pharmacological features known for native I K1 , including current enhancement by external potassium and voltage-and concentration-dependent blockade by external barium. Furthermore, the K ir inhibitors ML133, PA-6, and chloroquine, as well as the multichannel inhibitors chloroethylclonidine, chlorpromazine, SKF-96365, and the class III antiarrhythmic agent terikalant demonstrated slowly developing inhibitory activity in the low micromolar range. The robustness of this assay authorizes medium throughput screening for cardiosafety purposes and could help to enrich the currently limited K ir 2.1 pharmacology.
INTRODUCTION

I
nhibition of the voltage-dependent potassium channels K v 11.1, also referred to as human Ether-à-go-go Related Gene (hERG), which mediates the delayed rectifier I Kr potassium current in the heart, has been identified in the 1990's as a central mechanism associated with ''Torsades de Pointe'' (TdP) arrhythmias and sudden cardiac death. This major cardiosafety issue caused the market withdrawal of a significant number of pharmaceuticals. 1 Disruption of hERG function slows the repolarization phase of the cardiac action potential (AP), increasing its duration and favoring the initiation of early after depolarizations and ventricular arrhythmia, which can degenerate in TdP. 2 In accordance with internationally harmonized guidelines, 3, 4 these findings prompted the systematic early cardiosafety benefit/risk assessment of new drug candidates through evaluation of their functional effects at hERG channels in vitro, along with action potential duration (APD) measurements in ex vivo ventricular conductive tissue preparations such as rabbit Purkinje fibers. 5, 6 These studies are combined with in vivo measurements of the time interval between Q-wave and T-wave (QT) on the electrocardiogram, typically conducted in conscious dogs, 6, 7 and are followed as appropriate by specific thorough QT (TQT) studies during the early clinical development phases.
Despite the fact that these guidelines resulted in no further drugs being withdrawn from the market for arrhythmia liabilities since their implementation, the consistency of the surrogate markers examined as unequivocal predictors of TdP risk has recently been challenged. In addition, their stringency when taken individually as compound prioritization criteria may have generated unnecessary attrition of otherwise efficient and innovative drugs. For example, it has been shown that among nearly one hundred preclinical compounds, hERG inhibition translates into APD prolongation in only half of the cases, with one-third revealing no activity on APD, and onesixth actually shortening it. Moreover, it was shown that drugs either prolonging or shortening the APD could produce ventricular arrhythmia, at least in excised hearts. 8 Similarly, a retrospective analysis of several tens of advanced candidates, which underwent TQT studies in humans, showed that the predictive value of hERG inhibition alone, while being sensitive, substantially lacks specificity. 9 Hence, several drugs from various pharmacological classes with diverse chemical structures do not induce proarrhythmia in clinical practice, despite being significant hERG inhibitors at therapeutically relevant concentrations. Kramer et al. 10 suggested that, for many of these drugs, the discordance could result from compensatory inhibitory activities at depolarizing cardiac ion channels other than hERG contributing to shape the AP. Specifically, it was shown that among 55 small molecules with a clinically documented high or low TdP risk, additional inhibitory activity at Ca V 1.2-mediated I Ca,L calcium currents (and to a lesser extend at Na V 1.5-mediated I Na peak sodium currents) better describes their cardiosafety profile compared to knowledge of hERG inhibition alone. The ongoing comprehensive in vitro proarrhythmia assay (CiPA) initiative is a public-private collaboration put in place a few years ago with the objective to propose better ways to predict the proarrhythmic potential of preclinical compounds. This endeavor proposes to address the cardiosafety risk of a compound by combining its inhibitory profile at multiple cardiac ion channels with the predictions of an in silico model of human ventricular electrophysiology previously trained with the inhibitory profile of clinical drugs with documented high, medium, or low torsadogenic potential. The predictions would then be optionally compared with actual measurements on stem cell-derived cardiomyocytes before being assessed by electrocardiography monitoring during the early phases of clinical development. The panel of channels selected for the CiPA profiling comprise the depolarizing Ca V 1.2-and Na V 1.5-mediated I Ca,L and I Na peak and late currents, as well as the repolarizing K v 11.1-, K v 7.1-, K v 4.3-, and K ir 2.1-mediated I Kr , I Ks , I to , and I K1 currents. [11] [12] [13] [14] [15] In this study, we have developed a medium throughput screening assay based on automated whole-cell patch-clamp recording of K ir 2.1-mediated I K1 currents. Inwardly rectifying K ir 2.1 potassium channels belong to a family of transmembrane proteins sharing the property to flux K + ions more readily in the inward than in the outward direction. This ''biological diode''-like behavior is linked to their voltage-dependent block by cytoplasmic polyamines or magnesium ions, which plug their conduction pore at depolarized voltages. 16, 17 K ir 2.1 and other members of the K ir 2.x subfamily display strong rectification properties and contribute thereby to the control of the membrane resting potential in excitable tissues by constantly dragging the membrane toward the K + equilibrium potential E K . They also support repolarization following AP firing (reviewed in refs. [18] [19] [20] [21] ).
Despite the dearth of selective and potent pharmacologic agents, 22 and the fact that several different K ir 2.x subunits expressed in the heart can assemble into functional heterotetramers, 23 27, 28 One important aspect of the evaluation of drug effect at multiple cardiac ion channels pertains to adopting profiling methods reliably assessing the intrinsic activity of test articles using unbiased functional readouts. Authier et al. 29 recently
published a survey on current practices in the pharmaceutical industry, indicating that patch-clamp electrophysiology on human ion channels expressed in cell lines is the most common approach to the CiPA ion channel strategy. The development in the last decade of automated planar patch-clamp systems providing gigaseal quality recordings allows sufficient throughput to adequately expedite early cardiosafety support for the curtailed optimization cycles of modern medicinal chemistry. In this study, we undertook the validation of a K ir 2.1 assay on such a platform, allowing rapid quantification of drug inhibitory activity to complement an integrated drug discovery cardiosafety liability assessment panel. ) and the sequential application of drug solutions at final test concentration, while whole-cell patch-clamp is maintained without interruption. 30 
MATERIALS AND METHODS
Automated Patch-Clamp
All recordings were performed at room temperature. Experiments aimed at characterizing the electrophysiological properties of the currents were conducted on biochips endowed with a unique pinhole orifice engineered at the bottom of each of the 48 wells of disposable measurement plates (i.e., single-hole QPlates). Currents were activated by application of a series of 500 ms-long square voltage pulses delivered every 90 s and incremented in 5 mV steps from a holding potential of -20 mV. Currents measured over 30 ms at the end of each step served to plot current-voltage (I-V) relationships. In some experiments, the external potassium Experiments aimed at characterizing the pharmacology of small molecules were conducted with 48-well measurement plates, each fitted with biochips perforated with 10 holes, so that each recording site sums up the signal from multiple cells (i.e., multi-hole QPlates). The voltage protocol used was a step-ramp protocol applied every 30 s, which first stepped the membrane from a holding potential of -20 mV down to -120 mV for 500 ms, then ramped it up to 0 mV over 1 s, and eventually stepped the membrane potential back to -20 mV, where the cells were held until the next voltage cycle. This protocol allowed for long-time (30 min) recordings comprising a stable baseline and ample space for the application of multiple drug concentrations in a row. Moreover, the voltage ramp permitted to check the recording quality over time by monitoring the stability of the zero-current reversal potential value. The size of the inward current measured at the end of the initial hyperpolarizing 500 ms-step to -120 mV was used to evaluate drug effect.
For all experiments, the intracellular recording buffer contained (in mM) 5.37 CaCl 2 , 1.75 MgCl 2 , 10 ethylene glycol tetraacetic acid, 10 HEPES, 120 KCl, and 4 Na 2 -ATP (pH 7.2, 300 mOsm) and the standard extracellular recording buffer contained (in mM) 2 CaCl 2 , 1 MgCl 2 , 10 HEPES, 4 KCl, 145 NaCl, and 10 Glucose (pH 7.4, 310 mOsm).
Drugs
All test articles were from Sanofi's internal libraries, except ML133 (CAS Number 1222781-70-5; Wang et al.
31
), which was obtained from a commercial source (Sigma-Aldrich, Saint-Quentin-Fallavier), and PA-6 (CAS Number 1199627-07-0, Takanari et al. 32 ), a pentamidine derivative, which was synthesized following published procedures and references therein. 32,33 Figure 5 depicts the structural formula and IUPAC chemical names of ML133, PA-6, and the five other smallmolecule inhibitors examined in this study. Compounds were dissolved as 10, 50, or 100 mM concentrated stocks in dimethyl sulfoxide (DMSO) using sonication as needed for complete dissolution, then aliquoted into capped polypropylene vials, and kept frozen at -20°C until use. On the day of study, stock solutions were diluted to the final concentrations intended for cell applications in standard 96-well microtiter plates (MTP) containing the extracellular buffer supplemented with 0.06% Pluronic F-68 TM (Gibco, ThermoFisher Scientific).
The latter surfactant was added to help slow unseen precipitation (if any) of poorly soluble drugs in the MTP wells upon dilution. 34 The final drug solutions also contained 0.3% residual DMSO from the dilution processes. The test article solutions were typically applied to the cells within 30 min of preparation. Concentration-response data were either AUTOMATED K IR 2.1 PATCH-CLAMP obtained from the cumulative applications of six increasing concentrations to the same cells within a given recording well, each concentration being exposed for 3 min, or by applying a single different concentration into given wells with an exposure duration extended to 15 min.
Data Handling
Current amplitude measurements and normalization for the fitting of concentration-response curves were done with Sophion's dedicated analysis software (Odense 5.6.4). Time course of current amplitude was visualized offline and analyzed following optional rundown compensation as needed using built-in routines proprietary to this software (uncorrected rundown measured in N = 5 vehicle-treated cells did not exceed 1% per min in single application experiments). All recordings for pharmacological determinations were concluded by the application of a supramaximal concentration (3 mM) of barium as full block. Residual leak currents remaining under full block (if any) were subtracted from precedent data points. A professional graphing package (Prism 7.02; GraphPad Software) was used for drawing exported current traces, plotting I-V curves, and performing statistical calculations. Half-maximal inhibitory concentrations (IC 50 ) were obtained by fitting the average of the two or the five last current amplitude readings at the end of each drug concentration exposure period in a cumulative or noncumulative application mode, respectively. A classical four-parameter Hill equation following normalization with respect to predrug baseline readings was used for data fitting to a sigmoidal curve with minimum and maximum constrained to 0% and 100%, respectively. Estimated IC 50 
RESULTS AND DISCUSSION
Electrophysiological Characterization
The upper part of Figure 1A illustrates the typical appearance of whole-cell currents recorded from stably transfected CHO cells induced to express the human KCNJ2 gene product. Inward or outward currents reaching steady state within a 100 ms developed when the membrane was stepped tens of mV below or above the K + -equilibrium potential (E K ), respectively ( Fig. 1A) . At more depolarized potentials, the current-voltage (I-V) relationship displayed a strongly inward rectifying profile. This profile fully concurs with the I-V outline of native ventricular I K1 currents. 35 Specifically, the amplitudes of the inward currents below E K grew linearly in proportion to the negativity of the membrane, reaching relatively large values at strong hyperpolarization (e.g., -2.3 -0.4 nA at -120 mV, N = 10, Fig. 1B ), whereas the positive currents above E K culminated at potentials around -60 to -50 mV (e.g., 0.31 -0.09 nA at -60 mV, N = 10, Fig. 1B ). Virtually no currents were detected in induced cells at potentials more positive than -20 mV (Fig. 1B) nor at any potential in noninduced CHO cells (Fig. 1A bottom) , even when the latter were stepped to very negative potentials (e.g., 0.07 -0.05 nA at -120 mV, N = 10), indicating the absence of endogenous I K1 -like currents in the host CHO cell line. The success rate of exploitable recordings obtained from single-hole QPlates routinely exceeded half of the 48 Fig. 2 ). Beyond these maxima, the I-V curves presented regions of negative slope conductance until complete extinction of the currents. Their steepness was also proportional to [K + ] out , and the superposition of the outward currents in these voltage regions of the I-V curves draw a series of typical ''cross-over'' patterns as previously described by others. 35, 37 In response to the increasing This property was used to document K ir 2.1 channels when they were first isolated by expression cloning in Xenopus oocytes. Figure 3 illustrates the effects of micromolar Ba 2+ concentrations on K ir 2.1-mediated I K1 currents activated by a step-ramp voltage protocol in KCNJ2 expressing CHO cells. As previously described by Kubo et al., 42 external Ba 2+ blocked the steadystate current more strongly toward the end of the hyperpolarizing pulses than the initial instantaneous current (Fig. 3A) . Moreover, this time-dependent inhibition was also voltage dependent, the channel block increasing when the membrane was stepped to more negative potentials (Fig. 3B) . Group data obtained from N = 3 single-hole recordings indicated that the inhibition of the inward current produced by 3 mM Ba 2+ reached 17% at -120 mV, increasing to 48% at -150 mV. Similarly, the 58% inhibition of the current afforded by 10 mM Ba
2+
at -120 mV rose to 77% at -150 mV. These properties result in characteristic changes in the I-V relationship profile in the presence of Ba 2+ (Fig. 3B) and Cs + ions (data not shown). Figure 3C depicts the time course of the effect of cumulative applications of increasing concentrations of Ba 2+ into a multi-hole recording well. The K ir 2.1-mediated I K1 currents stabilized within several minutes after whole-cell access.
As expected from a fast-acting pore blocker, the inhibitory effect of each cumulatively applied concentration of Ba 2+ fully developed within the first couple of voltage-protocol cycles immediately at the beginning of each 3-min application period. The IC 50 value (calculated from the average normalized inward current amplitudes collected at the two last voltage steps down to -120 mV of each incubation period) was estimated at 8.2 mM (95% CI: 7.6-8.8 mM, N = 6, Fig. 4 ). The Hill coefficient (n H ) associated to the sigmoidal fit of the normalized data was close to unity (n H = 1.03; 95% CI: 0.96-1.1), consistent with a mechanism involving a single ion blocking each channel pore according to first-order kinetics. Notwithstanding the voltage dependency of the blocking effect of Ba exhibiting full inhibitory activity immediately at the beginning of each application period. These blockers were less potent than Ba
, yielding IC 50 values of 833 mM (95% CI: 789-880 mM, N = 12) with n H = 1.07 (95% CI: 1.0-1.1), and 4,585 mM (95% CI: 4,308-4,881 mM, N = 11) with n H = 0.92 (95% CI: 0.87-0.98), respectively (Fig. 4) . The potency obtained for Cs + on human K ir 2.1 channels was one order of magnitude weaker than published data for mouse K ir 2.1 overexpressed in a murineerythroleukemia cell line (IC 50 = 91 mM at -100 mV, Abrams et al.
44
), raising the possibility that K ir 2.1 expression in a conspecific rather than ectopic cell environment affects voltage dependency of Cs + blockade. We did not find quantitative pharmacological data with which to compare our potency determinations for Sr 2+ ions.
There are currently no selective small-molecule K ir 2.1 inhibitors with nanomolar potency described in the literature. 22 Even in the realm of toxins isolated from the venom of poisonous species, which are a rich source of high affinity ion channel modulators, no K ir 2.1 selective peptide inhibitors have been described so far. 45 We therefore went on to characterize the pharmacology of the K ir 2.1-mediated I K1 currents expressed in CHO cells using seven small-molecule inhibitors displaying micromolar potencies in manual patch-clamp experiments (Fig. 5) . We started with the aromatic diamidine derivative PA-6, 32 the methoxybenzyl-methanamide ML133, 31 and the antimalaria drug chloroquine 46 using the six-point cumulative application paradigm adopted with Ba 2+ and the other ionic pore blockers. However, the active concentrations of these weak amines did not reach full inhibition within the 3-min exposure periods. Previous studies comparing the inhibitory activity of these compounds in the inside-out and whole-cell patch-clamp configurations evidenced an accelerated inhibition rate and increased potency against K ir 2.1 currents when excised patches were assayed. These data pointed to cytoplasmic sites of actions for these three compounds, and further studies with mutants established the involvement of negatively charged glutamate and aspartate residues at the level of the cytoplasmic K ir 2.1 pore domain. 31, 32, 46 In the automated patch-clamp configuration, the time course for inhibition observed for such weak amine test articles applied externally results therefore from a combination of association kinetics at their internal sites of action and 
53
AUTOMATED K IR 2.1 PATCH-CLAMP membrane permeation of their uncharged molar fraction at neutral pH. Entry by organic cation transporters has been shown for pentamidine, 47 but it remains to be established whether such carriers are significantly expressed in CHO cells. We therefore adopted a noncumulative cell treatment protocol for the evaluation of PA-6, ML133, and chloroquine inhibitory potency. Cells were exposed to single concentrations of each compound in individual wells recorded in parallel. Figure 6A illustrates the time course of the effects of PA-6 when applied at concentrations ranging from 1.25 to 10 mM. Extension of the exposure duration to 15 min proved sufficient to reach stable inhibition for PA-6, ML133, and chloroquine. In contrast to Ba
2+
, the inhibitory action of PA-6 on the K ir 2.1 current traces indicated no time dependency during the hyperpolarizing pulse, displaying identical inhibition on its instantaneous and steady-state components (Fig. 6B) . The inhibitory potency of PA-6 calculated on the average current amplitudes collected over the five last voltage steps to -120 mV under drug exposure was IC 50 = 1.3 mM (95% CI: 1.2-1.4 mM, N = 3-5, Fig. 6B ) along with a Hill slope value near unity (n H = 1.2, 95% CI: 1.2-1.4, Table 1 ). When tested with the same prolonged 15-min exposure protocol, ML133 and chloroquine yielded micromolar potencies ( Table 1) . Hill coefficients were close to 1, except for ML133, suggesting a cooperative mechanism of action for this compound independent of its slow kinetics of action as proposed by others. 31 These inhibitory activities are consistent with published data obtained using traditional manual patch-clamp. Thus, whole-cell K ir 2.1 currents elicited at -110 mV in KCNJ2-tranfected HEK cells were inhibited by 68% in the presence of 3 mM external PA-6, 48 whereas ML133 showed an IC 50 value of 1.8 mM at -100 mV. 31 Similarly, in feline ventricular myocytes, 3 mM chloroquine decreased I K1 currents at -100 mV by 67%. 49 Only a few small-molecule K ir 2.1 inhibitors have their molecular mechanism of action deciphered, and this was not an objective of this study. We rather extended our efforts to assess structurally diverse K ir 2.1-preferring or Induced CHO cells were first exposed to vehicle alone for the time period shown before the vertical dashed line. Then, in control experiments (open circles), the cells were exposed to vehicle alone, while in drug treatment recordings, the cells were exposed to vehicle containing 1.25 mM (closed squares), 5 mM (closed triangles), or 10 mM (closed diamonds) PA-6 (twofold dilution series). The inhibitory activity was allowed to develop over 15 min. The average two measurements at the end of the last vehicle period and the average five measurements at the end of a drug treatment period served for current amplitude normalization. A final episode in each experiment consisted in the application of a saturating concentration of Ba 2+ as full block. (B) Representative multi-hole current traces in response to the voltage protocol shown above the traces. (C) Concentration-response curve for PA-6 inhibition using a threefold dilution series: IC 50 was estimated from at least N = 3 wells per concentration applied individually. See Table 1 for estimated value and 95% confidence interval.
multichannel inhibitors to generate a high-quality patchclamp data set for further pharmacological assay or protocol comparisons. Chloroethylclonidine, 50 chlorpromazine, 51 SKF-96365, 52 and the class III antiarrhythmic agent terikalant 53 are known to affect K ir 2.1-mediated I K1 currents in recombinant or native cell systems at micromolar concentrations. We first screened them with the cumulative concentration application mode and observed slow inhibition kinetics for all of them, suggesting common actions at the cytoplasmic side of the K ir 2.1 channels. We therefore used the single-concentration noncumulative parallel application mode also for these four compounds; results of these quantitative evaluations are reported in Table 1 . Only chloroethylclonidine appeared to reach fastenough steady-state inhibition fitting a cumulative mode evaluation, which doubled its apparent potency with an IC 50 56 However, expression of mammalian proteins in prokaryotic hosts could lead to folding alterations or yeast-specific glycosylations, which may potentially alter the channel pharmacology. Unfortunately, assays based on cardiomyocytes induced from human pluripotent stem cell cannot be used for the detection of K ir 2.1 inhibitors since they express insufficient amounts of I K1 to prevent them from spontaneously depolarizing and automatically beating. 57 Thus, the assay we describe in this study provides a useful tool for cardiovascular safety screening. Furthermore, it provides a platform for the discovery of novel K ir 2.1 channel ligands as drug candidates.
CONCLUSION
We have validated an automated patch-clamp assay for K ir 2.1 channels that reproduces cardinal features known for native I K1 currents and that generates concentration-response data for inhibitor tool compounds that agree with manual electrophysiology data. This assay is ready for cardiosafety screening of somewhat larger compound sets advancing toward preclinical development. 
